Predictors of controlled attenuation parameter in metabolic dysfunction.
CAP
LSM
abdominal circumference
controlled attenuation parameter
fasting insulin
fibroscan
liver stiffness measurement
metabolic syndrome
steatosis
thyroid
transient elastography
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
23 Dec 2023
23 Dec 2023
Historique:
received:
18
08
2023
accepted:
26
10
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
aheadofprint
Résumé
Hepatic fat content can be non-invasively estimated by controlled attenuation parameter (CAP) during transient elastography. The aim of this study was to examine the determinants and predictors of CAP values in individuals with metabolic dysfunction. We enrolled 1230 consecutive apparently healthy individuals (Liver-Bible-2022 cohort) with ≥3 metabolic dysfunction features. CAP was measured by Fibroscan. CAP determinants and predictors were identified using backward stepwise analysis and introduced in generalized linear models. Participants were predominantly males (82.9%), mean age was 53.8 ± 6.4 years, 600 (48.8%) had steatosis (CAP ≥ 275 dB/m), and 27 had liver stiffness measurement (LSM) ≥ 8 kPa. CAP values correlated with LSM (p < 10 Abdominal adiposity and insulin resistance severity were the main determinants of CAP in individuals with metabolic dysfunction and may improve steatotic liver disease risk stratification. CAP values were modulated by the hypophysis-thyroid axis.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Hepatic fat content can be non-invasively estimated by controlled attenuation parameter (CAP) during transient elastography. The aim of this study was to examine the determinants and predictors of CAP values in individuals with metabolic dysfunction.
METHODS
METHODS
We enrolled 1230 consecutive apparently healthy individuals (Liver-Bible-2022 cohort) with ≥3 metabolic dysfunction features. CAP was measured by Fibroscan. CAP determinants and predictors were identified using backward stepwise analysis and introduced in generalized linear models.
RESULTS
RESULTS
Participants were predominantly males (82.9%), mean age was 53.8 ± 6.4 years, 600 (48.8%) had steatosis (CAP ≥ 275 dB/m), and 27 had liver stiffness measurement (LSM) ≥ 8 kPa. CAP values correlated with LSM (p < 10
CONCLUSION
CONCLUSIONS
Abdominal adiposity and insulin resistance severity were the main determinants of CAP in individuals with metabolic dysfunction and may improve steatotic liver disease risk stratification. CAP values were modulated by the hypophysis-thyroid axis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gilead
ID : Gilead_IN-IT-989-5790
Organisme : Ministero della Salute
ID : RF-2016-02364358
Organisme : Ministero della Salute
ID : Rete Cardiologica "CV-PREVITAL"
Organisme : Ministero della Salute
ID : Ricerca Corrente
Organisme : AstraZeneca
ID : Astra Zeneca Agreement for Research
Organisme : Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
ID : Ricerca Corrente
Organisme : H2020 LEIT Information and Communication Technologies
ID : 101016726 - REVEAL
Organisme : Horizon 2020 Framework Program
ID : 777377 - Litmus project
Organisme : Novo Nordisk Project grants in Endocrinology and Metabolism
ID : NNF20OC0063883
Organisme : Vetenskapsrådet
ID : VR 2021-005208
Organisme : Knut och Alice Wallenbergs Stiftelse
ID : KAW 2017.0203
Organisme : Fondazione Patrimonio Ca' Granda
ID : "Liver BIBLE" (PR-0391)
Organisme : ALF Agreement
ID : SU 2018-04276
Organisme : Diabetesförbundet
ID : DIA2020-518
Organisme : Stiftelsen för Strategisk Forskning
ID : SSF ITM17-0384
Organisme : HORIZON EUROPE Framework Program
ID : 101096312 - GENIAL
Organisme : Hjärt-Lungfonden
ID : 20200191
Informations de copyright
© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. https://doi.org/10.1016/j.jhep.2023.06.003
Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564-568. https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-318813
Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74(4):775-782. https://doi.org/10.1016/j.jhep.2020.11.024
Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int. 2020;40(5):1016-1017. https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14430
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411-428. https://doi.org/10.1038/s41575-019-0145-7
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564-3573. https://doi.org/10.1007/s00330-019-06072-4
Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-1835. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. https://doi.org/10.1016/j.jhep.2016.12.022
Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. https://doi.org/10.1016/j.jhep.2021.05.025
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669. https://doi.org/10.1053/j.gastro.2021.07.049
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https://doi.org/10.1097/hep.0000000000000323
Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):134-144. https://doi.org/10.1002/hep.29489
Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, et al. Definition of healthy ranges for alanine aminotransferase levels: a 2021 update. Hepatol Commun. 2021;5(11):1824-1832. https://doi.org/10.1002/hep4.1794
Valenti L, Tripodi A, La Mura V, Pelusi S, Bianco C, Scalambrino E, et al. Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction. JHEP Rep. 2022;4(12):100598. https://doi.org/10.1016/j.jhepr.2022.100598
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. https://doi.org/10.1016/j.jhep.2008.02.008
Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182-1191. https://doi.org/10.1002/hep.25993
Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683-688. https://doi.org/10.1093/ajcn/75.4.683
van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449-457. https://onlinelibrary.wiley.com/doi/10.1002/hep.22350
Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Anthropometric and clinical factors associated with mortality in Subjects with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58(4):1132-1140. https://doi.org/10.1007/s10620-012-2446-3
De Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026-1031. https://doi.org/10.1016/j.jhep.2013.12.018
Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185-198. https://doi.org/10.1016/s2468-1253(20)30357-5
Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008;135(1):122-130. https://doi.org/10.1053/j.gastro.2008.03.021
Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711-724. https://doi.org/10.1002/hep.30429
Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(2):298. https://doi.org/10.3390/ijms20020298
Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7(2):125-134. https://doi.org/10.1016/j.cmet.2007.11.013
Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42(October):101092. https://doi.org/10.1016/j.molmet.2020.101092
Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356-370. https://doi.org/10.1111/joim.12719
Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Thyroid. 2018;28(10):1270-1284. https://www.liebertpub.com/doi/10.1089/thy.2018.0257
Qiu S, Cao P, Guo Y, Lu H, Hu Y. Exploring the causality between hypothyroidism and non-alcoholic fatty liver: a Mendelian randomization study. Front Cell Dev Biol. 2021;9(March):1-7. https://doi.org/10.3389/fcell.2021.643582
Bano A, Chaker L, Plompen EPC, Hofman A, Dehghan A, Franco OH, et al. Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study. J Clin Endocrinol Metab. 2016;101(8):3204-3211. https://doi.org/10.1210/jc.2016-1300
Bohinc BN, Michelotti G, Xie G, Pang H, Suzuki A, Guy CD, et al. Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology. 2014;155(11):4591-4601. https://doi.org/10.1210/en.2014-1302
Chung GE, Kim D, Kwak MS, Yim JY, Ahmed A, Kim JS. Longitudinal change in thyroid-stimulating hormone and risk of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021;19(4):848.e1-849.e1. https://doi.org/10.1016/j.cgh.2020.02.039
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012-2024. https://doi.org/10.1016/s0140-6736(19)32517-6
Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al. Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis. J Hepatol. 2023;78(Suppl 1):S1. https://doi.org/10.1016/s0168-8278(23)00440-3
Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2022;21(6):1523.e1-1532.e1. https://doi.org/10.1016/j.cgh.2022.03.044
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006:6.